Generic Name and Formulations:
Tigecycline 50mg/vial; lyophilized pwd for IV infusion after reconstitution and dilution; preservative-free.
Indications for TYGACIL:
Susceptible complicated skin and skin structure and intra-abdominal infections. Community-acquired bacterial pneumonia (CABP). Limitations of use: not for treating diabetic foot infection, hospital-acquired or ventilator-associated pneumonia.
≥18yrs: Give by IV infusion over 30–60 mins. 100mg once, then 50mg every 12hrs. Skin, skin structure, and intra-abdominal infections: treat for 5–14 days. CABP: treat for 7–14 days. Severe hepatic impairment (Child Pugh C): 100mg once, then 25mg every 12hrs.
<18yrs: not recommended. See full labeling for suggested dosages when no alternative antibacterial drugs are available.
Risk of increase in all-cause mortality; reserve for use when alternatives are not suitable. Monitor for hepatic dysfunction and pancreatitis; consider discontinuing if occurs. Ventilator-associated pneumonia. Complicated intra-abdominal infections secondary to intestinal perforation: avoid monotherapy (sepsis/septic shock may develop). Avoid during tooth development; may cause permanent discoloration of the teeth. Severe hepatic impairment. Pregnancy (Cat.D): not recommended. Nursing mothers.
Monitor warfarin. May antagonize oral contraceptives.
Nausea, vomiting, diarrhea, abdominal pain, headache, increased SGPT, inj site reactions, photosensitivity, pseudotumor cerebri; pancreatitis, superinfection, anaphylaxis, C. difficile-associated diarrhea (evaluate if occurs).
Single-use vials (5mL, 10mL)—10
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Behavioral Weight Loss Interventions May Prevent Obesity
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Executive Function Predicts T1D Management Into Emerging Adulthood
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- RET Inhibitor Gets Breakthrough Treatment Status for Medullary Thyroid Cancer
- Physical Activity as a Lifestyle Factor Influencing Early Menopause
- Situation Framing, Language Can Influence Decision-Making
- Gains in Insurance Coverage Seen for Lesbian, Gay, Bisexual Adults
- Oral Contraceptives Associated With Ventricular Repolarization Alterations